Activity from announced rounds
Euclidean Capital is the investor identified in Circle Pharma’s issuer announcement and by transaction counsel for InduPro.
Circle Pharma develops macrocycle medicines using computational and structure-based methods. The recorded history also includes Savvy Wealth’s operating tools and investment support for financial advisors. Multiple Savvy entries remain separate events pending their own event-level review.
Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
Develops neuro-metabolic therapeutics for schizophrenia and ALS
Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease